Company Profile

SomaGenics Inc (AKA: Somagenics Corporation)
Profile last edited on: 1/14/2019      CAGE: 1S9R0      UEI: NWMCAECH9RX7

Business Identifier: Novel RNA-based technologies to solve existing problems in diagnostics and drug development.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2161 Delaware Avenue Suite E
Santa Cruz, CA 95060
   (831) 426-7700
Location: Single
Congr. District: 18
County: Santa Cruz

Public Profile

Formed originally as a technology spin-out from SRI International, Somagenics is an early-phase biotechnology company focused on the development of a new class of molecules for controlling gene expression. Called RNA Lassos(tm), these molecules bind and inactivate specific messenger RNAs (mRNAs) that encode individual proteins. This platform technology has broad applications in treating disease, in defining the function of newly discovered genes and their usefulness as drug targets, and in gene-based diagnostics including microarrays. Somagenics will initially focus on the use of Lassos to treat rheumatoid arthritis (RA) and in providing target validation tools for the pharmaceutical industry. SomaGenics has developed a potent RNAi platform called sshRNA (synthetic short hairpin RNA). The sshRNA consists of a single RNA chain and has several advantages over conventional small interfering RNA (siRNA) and small hairpin (shRNA) structures used by others. Somagenics has focused on developing technologies for detecting and quantifying small RNAs such as miRNAs. The firm's miR-ID® is a versatile platform that provides sensitive and highly specific measurements of small RNAs. The miR-ID platform has been adapted for convenient detection of circulating miRNAs (miR-Direct TM), and a version has also been developed for the reliable detection of fragments of larger RNAs such as messenger RNAs from fresh and fixed tissue samples.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Brian H Johnston -- President and Founder

  Sergio Barberansoler

  Charlotte Clark -- Chief Business Officer

  Sergei A Kazakov -- Vice President for Discovery Research

  Catharina Lindley

  Anne Scholz -- Head of Business Development